Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Core Insights - The appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer highlights the Company's commitment to strengthening its leadership team while advancing its clinical and commercial strategy [1][3] Company Overview - Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [4] - The Company is developing NS002, an intranasal powder Epinephrine product candidate, as a needle-free alternative for patients experiencing anaphylaxis [4] Leadership Appointment - Eyal Rubin brings over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries to Nasus Pharma [1][2] - Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations [2] - The CEO and Executive Chairman expressed confidence in Mr. Rubin's ability to enhance the Company's financial and operational capabilities during a critical growth phase [3] Product Development - The Company's proprietary powder-based intranasal (PBI) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [4] - The PBI formulation utilizes uniform spherical powder particles for broad dispersion and potentially faster absorption compared to liquid-based nasal products [4]